CD33 and acute myeloid leukemia: Treatment with AMG330 showed that the simultaneous engagement of target cells (CD33+ AML blasts) and effector cells (CD3+ T cells) facilitated recruitment and expansion of effector T cells leading to the elimination of AML blasts even at very low effector-to-target ratios of up to 1:80 in vitro.